Cargando…

The prevalence and determinants of polypharmacy at age 69: a British birth cohort study

BACKGROUND: To describe the development of polypharmacy and its components in a British birth cohort in its seventh decade and to investigate socioeconomic and gender differences independent of disease burden. METHODS: Data from the MRC National Survey for Health and Development were analysed to det...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawle, Mark James, Richards, Marcus, Davis, Daniel, Kuh, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956732/
https://www.ncbi.nlm.nih.gov/pubmed/29769020
http://dx.doi.org/10.1186/s12877-018-0795-2
_version_ 1783323936639942656
author Rawle, Mark James
Richards, Marcus
Davis, Daniel
Kuh, Diana
author_facet Rawle, Mark James
Richards, Marcus
Davis, Daniel
Kuh, Diana
author_sort Rawle, Mark James
collection PubMed
description BACKGROUND: To describe the development of polypharmacy and its components in a British birth cohort in its seventh decade and to investigate socioeconomic and gender differences independent of disease burden. METHODS: Data from the MRC National Survey for Health and Development were analysed to determine the prevalence and composition of polypharmacy at age 69 and changes since ages 60 to 64. Multinomial regression was used to test associations between gender, education and occupational social class and total, cardiological and non-cardiological polypharmacy controlling for disease burden. RESULTS: At age 69, 22.8% of individuals were taking more than 5 medications. There was an increase in the use of 5 to 8 medications (+ 2.3%) and over 9 medications (+ 0.8%) between ages 60–64 and 69. The greatest increases were found for cardiovascular (+ 13.4%) and gastrointestinal medications (+ 7.3%). Men experienced greater cardiological polypharmacy, women greater non-cardiological polypharmacy. Higher levels of education were associated with lower polypharmacy independent of disease burden, with strongest effects seen for over five cardiological medications (RRR 0.3, 95% CI 0.2–0.5 p < 0.001 for advanced secondary qualifications compared with no qualification); there was no additional effect of social class. CONCLUSIONS: Polypharmacy increased over the seventh decade. Those with lower levels of education had more polypharmacy (total, cardiological and non-cardiological), even allowing for disease burden. Further analysis of future outcomes resulting from polypharmacy should take into account educational and gender differences, in an effort to identify at-risk populations who could benefit from medication reviews.
format Online
Article
Text
id pubmed-5956732
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59567322018-05-24 The prevalence and determinants of polypharmacy at age 69: a British birth cohort study Rawle, Mark James Richards, Marcus Davis, Daniel Kuh, Diana BMC Geriatr Research Article BACKGROUND: To describe the development of polypharmacy and its components in a British birth cohort in its seventh decade and to investigate socioeconomic and gender differences independent of disease burden. METHODS: Data from the MRC National Survey for Health and Development were analysed to determine the prevalence and composition of polypharmacy at age 69 and changes since ages 60 to 64. Multinomial regression was used to test associations between gender, education and occupational social class and total, cardiological and non-cardiological polypharmacy controlling for disease burden. RESULTS: At age 69, 22.8% of individuals were taking more than 5 medications. There was an increase in the use of 5 to 8 medications (+ 2.3%) and over 9 medications (+ 0.8%) between ages 60–64 and 69. The greatest increases were found for cardiovascular (+ 13.4%) and gastrointestinal medications (+ 7.3%). Men experienced greater cardiological polypharmacy, women greater non-cardiological polypharmacy. Higher levels of education were associated with lower polypharmacy independent of disease burden, with strongest effects seen for over five cardiological medications (RRR 0.3, 95% CI 0.2–0.5 p < 0.001 for advanced secondary qualifications compared with no qualification); there was no additional effect of social class. CONCLUSIONS: Polypharmacy increased over the seventh decade. Those with lower levels of education had more polypharmacy (total, cardiological and non-cardiological), even allowing for disease burden. Further analysis of future outcomes resulting from polypharmacy should take into account educational and gender differences, in an effort to identify at-risk populations who could benefit from medication reviews. BioMed Central 2018-05-16 /pmc/articles/PMC5956732/ /pubmed/29769020 http://dx.doi.org/10.1186/s12877-018-0795-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rawle, Mark James
Richards, Marcus
Davis, Daniel
Kuh, Diana
The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
title The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
title_full The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
title_fullStr The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
title_full_unstemmed The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
title_short The prevalence and determinants of polypharmacy at age 69: a British birth cohort study
title_sort prevalence and determinants of polypharmacy at age 69: a british birth cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956732/
https://www.ncbi.nlm.nih.gov/pubmed/29769020
http://dx.doi.org/10.1186/s12877-018-0795-2
work_keys_str_mv AT rawlemarkjames theprevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT richardsmarcus theprevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT davisdaniel theprevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT kuhdiana theprevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT rawlemarkjames prevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT richardsmarcus prevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT davisdaniel prevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy
AT kuhdiana prevalenceanddeterminantsofpolypharmacyatage69abritishbirthcohortstudy